0001179110-21-004122.txt : 20210402
0001179110-21-004122.hdr.sgml : 20210402
20210402180827
ACCESSION NUMBER: 0001179110-21-004122
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210401
FILED AS OF DATE: 20210402
DATE AS OF CHANGE: 20210402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zakrzewski Joseph S
CENTRAL INDEX KEY: 0001331852
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36065
FILM NUMBER: 21803252
MAIL ADDRESS:
STREET 1: 509 WATERVIEW PLACE
CITY: NEW HOPE
STATE: PA
ZIP: 18938
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACCELERON PHARMA INC
CENTRAL INDEX KEY: 0001280600
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-9200
MAIL ADDRESS:
STREET 1: 128 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
FORM 4 -
X0306
4
2021-04-01
0
0001280600
ACCELERON PHARMA INC
XLRN
0001331852
Zakrzewski Joseph S
128 SIDNEY STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2021-04-01
4
M
0
10000
24.11
A
44499
D
Common Stock
2021-04-01
4
S
0
104
132.61
D
44395
D
Common Stock
2021-04-01
4
S
0
6596
134.27
D
37799
D
Common Stock
2021-04-01
4
S
0
1700
135.22
D
36099
D
Common Stock
2021-04-01
4
S
0
1600
135.67
D
34499
D
Option to Purchase Common Stock
24.11
2021-04-01
4
M
0
10000
0
D
2023-12-05
Common Stock
10000
10000
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.57 to $133.50 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $133.62 to $134.61 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.62 to $135.51 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.64 to $135.73 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4.
The shares of common stock underlying this stock option award vested in equal quarterly installments over the first three years after the grant.
/s/ Adam M. Veness, as attorney-in-fact for Joseph S. Zakrzewski
2021-04-02